Recently published studies and systemic meta-analyses found that anti-PD-1 inhibitor-induced immune-related adverse events (including endocrine AEs) were strongly correlated with improved progression-free and overall survival in patients with non-small cell lung cancer (13), hepatocellular cancer (14), and other types of cancer (15). The gene discussed is PDCD1; the disease is cancer.